Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DKK3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DKK3 ECD-Fc / His-Tagged Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View DKK3 Products |
| Gene Delivery | DKK3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View DKK3 Products |
| Benchmark Ab | Anti-DKK3 Recombinant Antibody Recombinant positive control derived from clinical-stage/benchmark sequences. |
View DKK3 Products |
| Validator | DKK3 siRNA Set For target knockdown and specificity validation in cell-based assays. |
View DKK3 Products |
| Related Target A | CKAP4 Key functional receptor mediating DKK3-induced signaling pathways in cancer and fibrosis. |
View CKAP4 Products |
| Related Target B | LRP6 Wnt co-receptor involved in the modulation of canonical Wnt/beta-catenin signaling. |
View LRP6 Products |
| Related Target C | DKK1 Paralog target used for counter-screening to ensure antibody selectivity. |
View DKK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Loss of Native Glycosylation | HEK293 mammalian expression ensures correct N-glycosylation and native folding of DKK3. |
| Cross-Family Off-Target Binding | DKK1, DKK2, and DKK4 recombinant proteins available for rigorous selectivity profiling. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included in the portfolio. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live DKK3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development targeting DKK3 (Dickkopf-3) is expanding across two major fronts: oncology and fibrotic diseases. In oncology, DKK3 has a dual role; while it acts as a tumor suppressor in certain epithelial cancers (leading to the development of Ad-REIC/DKK3 gene therapies), it is highly upregulated in the stroma of other cancers (e.g., pancreatic and ovarian), driving immunosuppression and chemoresistance. Concurrently, DKK3 has emerged as a critical driver of tissue fibrosis (renal and cardiac) by modulating the Wnt/beta-catenin pathway. The race for DKK3 therapeutics is intensifying, with major players shifting focus from traditional gene therapies to targeted monoclonal antibodies and combination regimens that address the microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (Ad-DKK3) | Momotaro-Gene, OrganoTherapeutics | Prostate Cancer, Mesothelioma | Transfection efficiency and expression validation (Need Lentivirus/Promise-ORF) |
| Monoclonal Antibody (mAb) | Academic Institutions, Biotech Startups | Renal Fibrosis, Pancreatic Cancer | Affinity determination and blocking assays (Need high-purity HEK293-expressed ECD-Fc) |
| Small Molecule/Peptide | Preclinical Discovery Programs | Fibrotic Disorders, Heart Failure | High-throughput screening and selectivity panels (Need DKK family proteins) |